Evidence map›Paper›PMID 26918818›Full record

ArticlePloS one2016

Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.

Sreenivas Achuthan Nair, Neeraj Raizada, Kuldeep Singh Sachdeva, Claudia Denkinger, Samuel Schumacher, Puneet Dewan, Shubhangi Kulsange, Catharina Boehme, Chinnambedu Nainarappan Paramsivan, Nimalan Arinaminpathy

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Drug Resistance ofJournal of immunology research · 2023
    Article
  7. Rifampicin resistantSAGE open medicine · 2023
    Article
  8. Article
  9. Article
  10. Proportion and trend of primary resistance among Multidrug resistant Tuberculosis patients in Ethiopia.Journal of clinical tuberculosis and other mycobacterial diseases · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Sreenivas Achuthan NairWorld Health Organization, Country Office for India, New Delhi, India.
Neeraj RaizadaFoundation for Innovative New Diagnostics, New Delhi, India.
Kuldeep Singh SachdevaCentral TB Division, Government of India, New Delhi, India.
Claudia DenkingerFoundation for Innovative New Diagnostics, New Delhi, India.
Samuel SchumacherFoundation for Innovative New Diagnostics, New Delhi, India.
Puneet DewanBill and Melinda Gates Foundation, New Delhi, India.
Shubhangi KulsangeFoundation for Innovative New Diagnostics, New Delhi, India.
Catharina BoehmeFoundation for Innovative New Diagnostics, New Delhi, India.
Chinnambedu Nainarappan ParamsivanFoundation for Innovative New Diagnostics, New Delhi, India.
Nimalan ArinaminpathyDepartment of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
Gates Foundation · USGovernment of India · INImperial College London · GBWorld Health Organization - India · IN

Funding

Medical Research Council MR/K010174/1World Health Organization 001
6 · The paper itself

Abstract

backgroundTuberculosis remains a major public health challenge for India. Various studies have documented different levels of TB and multi-drug resistant (MDR) TB among diverse groups of the population. In view of renewed targets set under the End TB strategy by 2035, there is an urgent need for TB diagnosis to be strengthened. Drawing on data from a recent, multisite study, we address key questions for TB diagnosis amongst symptomatics presenting for care: are there subgroups of patients that are more likely than others, to be positive for TB? In turn, amongst these positive cases, are there factors-apart from treatment history-that may be predictive for multi-drug resistance?

methodsWe used data from a multi-centric prospective demonstration study, conducted from March 2012 to December 2013 in 18 sub-district level TB programme units (TUs) in India and covering a population of 8.8 million. In place of standard diagnostic tests, upfront Xpert MTB/RIF testing was offered to all presumptive TB symptomatics. Here, using data from this study, we used logistic regression to identify association between risk factors and TB and Rifampicin-Resistant TB among symptomatics enrolled in the study.

resultsWe find that male gender; history of TB treatment; and adult age compared with either children or the elderly are risk factors associated with high TB detection amongst symptomatics, across the TUs. While treatment history is found be a significant risk factor for rifampicin-resistant TB, elderly (65+ yrs) people have significantly lower risk than other age groups. However, pediatric TB cases have no less risk of rifampicin resistance as compared with adults (OR 1.23 (95% C.I. 0.85-1.76)). Similarly, risk of rifampicin resistance among both the genders was the same. These patterns applied across the study sites involved. Notably in Mumbai, amongst those patients with microbiological confirmation of TB, female patients showed a higher risk of having MDR-TB than male patients.

conclusionOur results cast fresh light on the characteristics of symptomatics presenting for care who are most likely to be microbiologically positive for TB, and for rifampicin resistance. The challenges posed by TB control are complex and multifactorial: evidence from diverse sources, including retrospective studies such as that addressed here, can be invaluable in informing future strategies to accelerate declines in TB burden.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsAntibiotics, AntitubercularChildDrug Resistance, BacterialFemaleHumansIndiaMaleMiddle AgedRetrospective StudiesRifampinRisk FactorsAntibiotics, AntitubercularRifampin

Identifiers

PMID26918818
PMCPMC4769074
OpenAlexW2281127377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.